This inventor holds 1 USPTO granted patent. Top assignee: Hoechst Aktiengesellschaft. Active years: 2005.
Company Filing History:
Years Active: 2005
Title: **Michael Dörschug: Innovator in Diabetes Treatment**
Introduction
Michael Dörschug, a notable inventor based in Bochum, Germany, has made significant contributions to the field of diabetes treatment through his innovative work in biochemistry. As an employee of Hoechst Aktiengesellschaft, Dörschug's research has led to the development of a unique mini-proinsulin that holds promise for pharmaceutical applications.
Latest Patents
Dörschug is credited with one patent titled "Mini-proinsulin, its preparation and use." This innovative mini-proinsulin replaces the traditional C chain with an amino acid Arg bridging the A and B chains. The result is a compound that not only exhibits insulin activity but also has practical applications in treating diabetes mellitus. Notably, this mini-proinsulin can be easily converted into an insulin derivative with the use of trypsin, and further into insulin via carboxypeptidase B. The process is simplified by allowing a one-pot conversion directly to insulin, presenting a significant advancement in diabetes treatment methodologies.
Career Highlights
Throughout his career at Hoechst Aktiengesellschaft, Dörschug has focused on developing effective treatments for diabetes, leveraging his extensive knowledge in biochemistry. His patent reflects a keen understanding of both theoretical and practical aspects of insulin preparation, marking a highlight in his professional journey.
Collaborations
In his research pursuits, Dörschug has collaborated with esteemed colleagues such as Paul Habermann and Gerhard Seipke. Their joint efforts have contributed to advancements in diabetes treatment, showcasing a collective dedication to improving patient outcomes through innovative therapies.
Conclusion
Michael Dörschug's contributions to diabetes treatment through his patented mini-proinsulin are commendable. His work exemplifies the intersection of innovative research and practical application, promising to enhance the lives of those affected by diabetes mellitus. As research continues, his developments are likely to play a pivotal role in future pharmaceutical advancements.